Improvement of epirubicin-induced phlebitis to switch from liquid preparation to lyophilized formulation

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 1, 2009, Pages 93-96

  Suga, Yukio ^a,b   Kumazaki, Masafumi ^a   Nishigami, Jun ^b   Takeda, Kazuyoshi ^b   Kawagishi, Atsufumi ^b   Ishizaki, Junko ^a   Inokuchi, Masafumi ^b   Miyamoto, Ken Ichi ^b   Arai, Kunizo ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Breast cancer; Epirubicin; Phlebitis

Indexed keywords

EPIRUBICIN; STEROID;

ARTICLE; BREAST CANCER; CLINICAL EVALUATION; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG FORMULATION; HUMAN; LIQUID; MAJOR CLINICAL STUDY; MORBIDITY; OINTMENT; PERIPHERAL VEIN; PHLEBITIS;

EID: 79959858723     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Martine JP, Angelo DL, Marc B, et al: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19: 3103-3110, 2001.
2. Kahán Z, Spanik S, Wagnerova M, et al: Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG). Breast Cancer Res Treat. 2008 Jan 13; [Epub ahead of print]
3. Toi M, Nakamura S, Kuroi K, et al: Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat. 110 (3): 531-539, 2008. [Epub 2007 Sep 19] (Pubitemid 351962591)
4. Anami S, Masuda N, Nishikata M, et al: Factors of associated with pllebitis and venous pain due to intravenous injection of epirubicin hydrochloride. Jpn J Pharm Health Care Sci 32: 1105-1110, 2006.